[시장보고서]신경 자극 기기 시장 : 규모, 점유율, 동향 분석, 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

신경 자극 기기 시장 : 규모, 점유율, 동향 분석, 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Neurostimulation Devices Market Size, Share & Trends Analysis Report By Product, By Applications, By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869660

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,833,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,318,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,288,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

신경 자극 기기 시장 요약

세계 신경 자극 기기 시장 규모는 2024년 58억 달러로 평가되었고, 2033년까지 139억 3,000만 달러에 이를 것으로 예측됩니다.

2025-2033년에 걸친 CAGR은 10.29%를 나타낼 전망입니다. 시장의 성장은 신경질환의 유병률 증가, 낮은 침습 요법에 대한 선호도 증가, 장기 통증 관리 솔루션에 대한 수요 증가로 인한 것입니다.

폐쇄 루프 자극, MRI 지원 장치 및 배터리 수명 향상과 같은 기술적 진보는 치료 정밀도와 환자 결과를 향상시켜 임상 현장에서의 보급을 촉진하고 있습니다. 또한, 만성 통증, 간질, 파킨슨병, 우울증, 척수 손상 등의 신경 자극 요법의 적용 범위 확대와 많은 지역의 지원적인 상환 정책이 시장 성장을 더욱 가속화하고 있습니다.

정부 자금 증가는 신경 자극 기기 시장의 주요 촉진요인입니다. 이것은 첨단 신경 자극 기술의 개발을 가속화하고 치료 응용 범위를 확대하기 위해서입니다. 정부가 연구 프로그램, 임상시험, 혁신 이니셔티브에 자금을 배분함으로써 신경질환의 깊은 이해가 가능해지고, 신경자극을 이용한 치료방법에 있어서의 획기적인 진전이 지원됩니다. 이 재정적 지원은 연구자, 임상의, 의료기기 개발자 간의 협력을 촉진하고 안전성, 정확성 및 환자 결과가 향상된 차세대 시스템의 상업화를 뒷받침합니다. 또한, 의료 접근성 향상과 신경질환 치료 비용 부담 경감을 목표로 하는 정부의 이니셔티브는 간접적으로 신경자극요법의 도입을 촉진하고, 보다 광범위한 환자층에의 보급을 확대함으로써 시장 전체의 성장을 견인하고 있습니다.

부문 대시보드
세계의 신경 자극 기기 시장 : 제품별 변동 분석, 2024년 및 2033년
세계의 신경 자극 기기 시장 규모와 동향 분석 : 제품별, 2021-2033년
척수 자극 기기
뇌심부 자극 기기
천골신경 자극 기기
미주 신경 자극 기기
위 전기 자극
기타

제5장 신경 자극 기기 시장 : 용도별 추정·동향 분석

부문 대시보드
세계의 신경 자극 기기 시장 : 용도별 변동 분석, 2024년 및 2033년
세계의 신경 자극 기기 시장 규모와 동향 분석 : 용도별, 2021-2033년
파킨슨병
만성 통증
편두통
간질
진전
우울
요실금 및 변실금
기타

제6장 신경 자극 기기 시장 : 최종 용도별 추정·동향 분석

부문 대시보드
세계의 신경 자극 기기 시장 : 최종 용도별 변동 분석, 2024년 및 2033년
세계의 신경 자극 기기 시장 규모와 동향 분석 : 최종 용도별, 2021-2033년
병원·외래수술센터(ASC)
클리닉· 물리치료 센터
기타

제7장 신경 자극 기기 시장 : 지역별 추정·동향 분석

지역 대시보드
시장 규모와 동향 분석, 2021-2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 스웨덴
- 덴마크
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업 분류
2023년 기업의 시장 점유율 분석
기업 히트맵 분석
전략 매핑
- 확대
- 합병과 인수
- 파트너십 및 협업
- 신제품 발매
- 연구개발
- 기업 프로파일
- Abbott(St. Jude Medical)
- Medtronic
- Boston Scientific Corporation
- Aleva Neurotherapeutics
- Nexstim
- LivaNova PLC
- Neuropace Inc.
- Nevro Corporation
- electroCore, Inc.
- Axonics, Inc.
- Nalu Medical
- Mainstay Medical
- Saluda Medical Pty Ltd
- Biotronik
- MicroTransponder Inc.
- tVNS Technologies GmbH
- Laborie

SHW

영문 목차

영문목차

Neurostimulation Devices Market Summary

The global neurostimulation devices market size was estimated at USD 5.80 billion in 2024 and is projected to reach USD 13.93 billion by 2033, growing at a CAGR of 10.29% from 2025 to 2033. The growth of the market is attributed due to the rising prevalence of neurological disorders, growing preference for minimally invasive therapies, and increasing demand for long-term pain management solutions.

Technological advancements such as closed-loop stimulation, MRI-compatible devices, and improved battery life enhance treatment precision and patient outcomes, driving wider clinical acceptance. In addition, expanding applications of neurostimulation in conditions such as chronic pain, epilepsy, Parkinson's disease, depression, and spinal cord injuries, along with supportive reimbursement policies in many regions, are further accelerating market growth.

Growing government funding for neuroscience research is a key driver of the neurostimulation devices market, as it accelerates the development of advanced neurostimulation technologies and expands therapeutic applications. By allocating capital to research programs, clinical trials, and innovation initiatives, governments enable a deeper understanding of neurological disorders and support breakthroughs in treatment approaches using neurostimulation. This financial backing fosters collaboration among researchers, clinicians, and medical device developers and encourages the commercialization of next-generation systems with improved safety, precision, and patient outcomes. Furthermore, government initiatives aimed at enhancing healthcare accessibility and reducing the cost burden of neurological care indirectly promote the adoption of neurostimulation therapies, expanding their reach to a broader patient base and fueling overall market growth.

Global Neurostimulation Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global neurostimulation devices market report on the basis of product, application, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Spinal Cord Stimulators
Deep Brain Stimulators
Sacral Nerve Stimulators
Vagus Nerve Stimulators
Gastric Electrical Stimulation
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Parkinson's Disease
Chronic Pain
Migraine
Epilepsy
Tremor
Depression
Urinary & Fecal Incontinence
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals & Ambulatory Surgery Centers (ASC)
Clinics & Physiotherapy Centers
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
1.5. Details of primary research
- 1.5.1. Data for primary interviews in North America
- 1.5.2. Data for primary interviews in Europe
- 1.5.3. Data for primary interviews in Asia Pacific
- 1.5.4. Data for primary interviews in Latin America
- 1.5.5. Data for Primary interviews in MEA
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
  - 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.2. Volume price analysis (Model 2)
  - 1.7.2.1. Approach 2: Volume price analysis
1.8. Research Scope and Assumptions
- 1.8.1. List of Secondary Sources
- 1.8.2. List of Primary Sources
- 1.8.3. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Neurostimulation Devices Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
  - 3.2.1.1. Government funding for research and development
  - 3.2.1.2. Technological advancements in neurostimulation devices
  - 3.2.1.3. Increasing prevalence of neurological disorders
  - 3.2.1.4. Growing reimbursement coverage
  - 3.2.1.5. Expanding applications
- 3.2.2. Market Restraints Analysis
  - 3.2.2.1. Complex regulatory framework
  - 3.2.2.2. Surgery-associated risk
3.3. Neurostimulation Devices Market Analysis Tools
- 3.3.1. Porter's Analysis
  - 3.3.1.1. Bargaining power of the suppliers
  - 3.3.1.2. Bargaining power of the buyers
  - 3.3.1.3. Threats of substitution
  - 3.3.1.4. Threats from new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Economic and Social landscape
  - 3.3.2.3. Technological landscape
  - 3.3.2.4. Environmental landscape
  - 3.3.2.5. Legal landscape

Chapter 4. Neurostimulation Devices Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Neurostimulation Devices Market: Product Movement Analysis, 2024 & 2033 (USD Million)
4.3. Global Neurostimulation Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Spinal Cord Stimulators
- 4.4.1. Spinal cord stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Deep Brain Stimulators
- 4.5.1. Deep brain stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Sacral Nerve Stimulators
- 4.6.1. Sacral nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.7. Vagus Nerve Stimulators
- 4.7.1. Vagus nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.8. Gastric Electrical Stimulation
- 4.8.1. Gastric electrical stimulation market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.9. Others
- 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Neurostimulation Devices Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Neurostimulation Devices Market: Application Movement Analysis, 2024 & 2033 (USD Million)
5.3. Global Neurostimulation Devices Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
5.4. Parkinson's Disease
- 5.4.1. Parkinson's disease market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Chronic Pain
- 5.5.1. Chronic pain market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Migraine
- 5.6.1. Migraine market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.7. Epilepsy
- 5.7.1. Epilepsy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.8. Tremor
- 5.8.1. Tremor market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.9. Depression
- 5.9.1. Depression market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.10. Urinary & Fecal Incontinence
- 5.10.1. Urinary & fecal incontinence market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.11. Others
- 5.11.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Neurostimulation Devices Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Neurostimulation Devices Market: End use Movement Analysis, 2024 & 2033 (USD Million)
6.3. Global Neurostimulation Devices Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
6.4. Hospitals & Ambulatory Surgery Centers (ASC)
- 6.4.1. Hospitals & Ambulatory Surgery Centers (ASC) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Clinics & Physiotherapy Centers
- 6.5.1. Clinics & physiotherapy centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Neurostimulation Devices Market: Regional Estimates & Trend Analysis by Product, Application and End Use

7.1. Regional Dashboard
7.2. Market Size and Trend Analysis, 2021 to 2033
7.3. North America
- 7.3.1. North America neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Competitive scenario
  - 7.3.2.3. Regulatory framework
  - 7.3.2.4. Reimbursement scenario
  - 7.3.2.5. U.S. neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Competitive scenario
  - 7.3.3.3. Regulatory framework
  - 7.3.3.4. Reimbursement scenario
  - 7.3.3.5. Canada neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key country dynamics
  - 7.3.4.2. Competitive scenario
  - 7.3.4.3. Regulatory framework
  - 7.3.4.4. Reimbursement scenario
  - 7.3.4.5. Mexico neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.4. Europe
- 7.4.1. Europe neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Competitive scenario
  - 7.4.2.3. Regulatory framework
  - 7.4.2.4. Reimbursement scenario
  - 7.4.2.5. UK neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Competitive scenario
  - 7.4.3.3. Regulatory framework
  - 7.4.3.4. Reimbursement scenario
  - 7.4.3.5. Germany neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Competitive scenario
  - 7.4.4.3. Regulatory framework
  - 7.4.4.4. Reimbursement scenario
  - 7.4.4.5. France neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Competitive scenario
  - 7.4.5.3. Regulatory framework
  - 7.4.5.4. Reimbursement scenario
  - 7.4.5.5. Italy neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Competitive scenario
  - 7.4.6.3. Regulatory framework
  - 7.4.6.4. Reimbursement scenario
  - 7.4.6.5. Spain neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Competitive scenario
  - 7.4.7.3. Regulatory framework
  - 7.4.7.4. Reimbursement scenario
  - 7.4.7.5. Sweden neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Competitive scenario
  - 7.4.8.3. Regulatory framework
  - 7.4.8.4. Reimbursement scenario
  - 7.4.8.5. Denmark neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
  - 7.4.9.1. Key country dynamics
  - 7.4.9.2. Competitive scenario
  - 7.4.9.3. Regulatory framework
  - 7.4.9.4. Reimbursement scenario
  - 7.4.9.5. Norway neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Competitive scenario
  - 7.5.2.3. Regulatory framework
  - 7.5.2.4. Reimbursement scenario
  - 7.5.2.5. China neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Japan
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Competitive scenario
  - 7.5.3.3. Regulatory framework
  - 7.5.3.4. Reimbursement scenario
  - 7.5.3.5. Japan neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Competitive scenario
  - 7.5.4.3. Regulatory framework
  - 7.5.4.4. Reimbursement scenario
  - 7.5.4.5. India neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Competitive scenario
  - 7.5.5.3. Regulatory framework
  - 7.5.5.4. Reimbursement scenario
  - 7.5.5.5. South Korea neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Australia
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Competitive scenario
  - 7.5.6.3. Regulatory framework
  - 7.5.6.4. Reimbursement scenario
  - 7.5.6.5. Australia neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Thailand
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Competitive scenario
  - 7.5.7.3. Regulatory framework
  - 7.5.7.4. Reimbursement scenario
  - 7.5.7.5. Thailand neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.6. Latin America
- 7.6.1. Latin America neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Competitive scenario
  - 7.6.2.3. Regulatory framework
  - 7.6.2.4. Reimbursement scenario
  - 7.6.2.5. Brazil neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Competitive scenario
  - 7.6.3.3. Regulatory framework
  - 7.6.3.4. Reimbursement scenario
  - 7.6.3.5. Argentina neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
7.7. Middle East and Africa
- 7.7.1. Middle East and Africa neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Competitive scenario
  - 7.7.2.3. Regulatory framework
  - 7.7.2.4. Reimbursement scenario
  - 7.7.2.5. South Africa neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Competitive scenario
  - 7.7.3.3. Regulatory framework
  - 7.7.3.4. Reimbursement scenario
  - 7.7.3.5. Saudi Arabia neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Competitive scenario
  - 7.7.4.3. Regulatory framework
  - 7.7.4.4. Reimbursement scenario
  - 7.7.4.5. UAE neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
  - 7.7.5.1. Key country dynamics
  - 7.7.5.2. Competitive scenario
  - 7.7.5.3. Regulatory framework
  - 7.7.5.4. Reimbursement scenario
  - 7.7.5.5. Kuwait neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Market Share Analysis, 2023
8.4. Company Heat Map Analysis
8.5. Strategy Mapping
- 8.5.1. Expansion
- 8.5.2. Mergers & Acquisition
- 8.5.3. Partnerships & Collaborations
- 8.5.4. New Product Launches
- 8.5.5. Research And Development
- 8.5.6. Company Profiles
- 8.5.7. Abbott (St. Jude Medical)
  - 8.5.7.1. Company overview
  - 8.5.7.2. Financial performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic initiatives
- 8.5.8. Medtronic
  - 8.5.8.1. Company overview
  - 8.5.8.2. Financial performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic initiatives
- 8.5.9. Boston Scientific Corporation
  - 8.5.9.1. Company overview
  - 8.5.9.2. Financial performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic initiatives
- 8.5.10. Aleva Neurotherapeutics
  - 8.5.10.1. Company overview
  - 8.5.10.2. Financial performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic initiatives
- 8.5.11. Nexstim
  - 8.5.11.1. Company overview
  - 8.5.11.2. Financial performance
  - 8.5.11.3. Product Benchmarking
  - 8.5.11.4. Strategic initiatives
- 8.5.12. LivaNova PLC
  - 8.5.12.1. Company overview
  - 8.5.12.2. Financial performance
  - 8.5.12.3. Product Benchmarking
  - 8.5.12.4. Strategic initiatives
- 8.5.13. Neuropace Inc.
  - 8.5.13.1. Company overview
  - 8.5.13.2. Financial performance
  - 8.5.13.3. Product Benchmarking
  - 8.5.13.4. Strategic initiatives
- 8.5.14. Nevro Corporation
  - 8.5.14.1. Company overview
  - 8.5.14.2. Financial performance
  - 8.5.14.3. Product Benchmarking
  - 8.5.14.4. Strategic initiatives
- 8.5.15. electroCore, Inc.
  - 8.5.15.1. Company overview
  - 8.5.15.2. Financial performance
  - 8.5.15.3. Product Benchmarking
  - 8.5.15.4. Strategic initiatives
- 8.5.16. Axonics, Inc.
  - 8.5.16.1. Company overview
  - 8.5.16.2. Financial performance
  - 8.5.16.3. Product Benchmarking
  - 8.5.16.4. Strategic initiatives
- 8.5.17. Nalu Medical
  - 8.5.17.1. Company overview
  - 8.5.17.2. Financial performance
  - 8.5.17.3. Product Benchmarking
  - 8.5.17.4. Strategic initiatives
- 8.5.18. Mainstay Medical
  - 8.5.18.1. Company overview
  - 8.5.18.2. Financial performance
  - 8.5.18.3. Product Benchmarking
  - 8.5.18.4. Strategic initiatives
- 8.5.19. Saluda Medical Pty Ltd
  - 8.5.19.1. Company overview
  - 8.5.19.2. Financial performance
  - 8.5.19.3. Product Benchmarking
  - 8.5.19.4. Strategic initiatives
- 8.5.20. Biotronik
  - 8.5.20.1. Company overview
  - 8.5.20.2. Financial performance
  - 8.5.20.3. Product Benchmarking
  - 8.5.20.4. Strategic initiatives
- 8.5.21. MicroTransponder Inc.
  - 8.5.21.1. Company overview
  - 8.5.21.2. Financial performance
  - 8.5.21.3. Product Benchmarking
  - 8.5.21.4. Strategic initiatives
- 8.5.22. tVNS Technologies GmbH
  - 8.5.22.1. Company overview
  - 8.5.22.2. Financial performance
  - 8.5.22.3. Product Benchmarking
  - 8.5.22.4. Strategic initiatives
- 8.5.23. Laborie
  - 8.5.23.1. Company overview
  - 8.5.23.2. Financial performance
  - 8.5.23.3. Product Benchmarking
  - 8.5.23.4. Strategic initiatives